Stock News and Filings Feed


Add TIG
to your dashboard

Grifols SA opens position in TGXSF / Tigenix Sa - Fintel.io

2017-07-13 fintel.io
July 13, 2017 - Grifols SA has filed a SC 13G form disclosing ownership of 41,929,954 shares of Tigenix Sa (OTC:TGXSF) corresponding to 16.1 percent ownership .

TiGenix Begins Recruiting for New U.S. HQ in Massachusetts

2017-06-29 biospace
Leuven (BELGIUM) - June 29, 2017, 11:30h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces it has opened an U.S. office in Cambridge, Massachusetts. Establishing U.S. operations is a significant step for TiGenix and will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn's disease patients, in the United States.

TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come

2017-06-27 seekingalpha
The biotech has signed a $400+ million deal with big pharma Takeda for its lead asset, Cx601, which should be approved in Europe before YE2017

TiGenix Announces Final Equity Payment For Cardiac Platform Acquisition

2017-06-12 devicespace
Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015.

TiGenix Announces Final Equity Payment For Cardiac Platform Acquisition

2017-06-12 devicespace
Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015.

TiGenix to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 23, 2017

2017-03-22 prnewswire
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

Pipeline of Congestive Heart Failure Market Review Research for H1 2017 - Reports and Reports

2017-03-22 prnewswire
ReportsnReports.com adds "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

2
shares
MIDEAST STOCKS-Depressed oil prices may continue to weigh on Gulf

2017-03-13 reuters
DUBAI, March 13 A further slide in oil prices may weigh on Gulf stock markets on Monday with Saudi Arabia's index possibly underperforming its peers becuase of that market's large petrochemical sector.

3
shares
BRIEF-Ipsen says MHRA has approved a new indication for Decapeptyl

2017-03-13 reuters
* Ipsen announces mhra1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

4
shares
BRIEF-Tigenix NV announces top-line one-year results from Caremi clinical trial

2017-03-13 reuters
* Tigenix NV - announced top-line one-year results from Caremi clinical trial, an exploratory phase I/II study of Allocscs in acute myocardial infarction

2
shares
BRIEF-Tigenix receives positive feedback from FDA on Cx601 global phase III trial protocol

2017-03-07 reuters
* Tigenix NV - received positive feedback from U.S. FDA on an improved protocol for its global phase III trial for treatment of complex perianal fistulas

TiGenix submits responses to requests from European regulators regarding Cx601 marketing application

2016-12-23 seekingalpha
Recent IPO TiGenix (Pending:TIG) announces that it has submitted its responses to the European Medicines Agency's Day 120 List of Questions regarding its Marketing Authorization Application (MAA) seeking approval for lead product candidate Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients.

U.S. IPO Weekly Recap: Last 3 IPOs Of 2016 Include Trivago Pricing Down And The Worst First Day Of The Year

2016-12-17 seekingalpha
This past week saw the last three IPOs of 2016 raise $735 million. IPO investors were stubborn until the end. All three had to price at large discounts to public peers and below expectations. Markets absorbed the Fed's long-anticipated rate hike and the news of three potential increases next year.

President Obama Signs 21st Century Cures Act - Implications For The Stem Cell Sector

2016-12-14 seekingalpha
Yesterday, President Obama signed into law the 21st Century Cures Act, a piece of legislation that had rare overwhelming bi-partisan support. The White House issued this statement about the legislation as it passed through Congress on November 30th:

U.S. IPO Week Ahead: 3 Deals Lined Up To Close Out 2016 IPO Market

2016-12-10 seekingalpha
Three companies are set to close out the 2016 IPO class in the upcoming week. Hotel search aggregator trivago, oil and gas E&P Wildhorse Resource Development and stemcell therapy company TiGenix are set to push the number of IPOs to 105 for the year.

TiGenix Provides Update on Proposed Initial Public Offering in the United States

2016-10-27 biospace
Leuven, Belgium, Oct. 26, 2016 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the filing of an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering in the United States of its American Depositary Shares ("ADSs"), initially filed on December 22, 2015.

Takeda nabs ex-U.S. rights to investigational stem cell treatment for Crohn's-related fistulas

2016-09-18 seekingalpha
Takeda Pharmaceutical Company (OTCPK:TKPHF)(OTCPK:TKPYY) inks an agreement with Belgian biotech TiGenix NV for the exclusive ex-U.S. rights to develop and commercialize the latter's Orphan Drug-tagged Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.

The Forgotten Stem Cell Sector Is Making Substantive Progress

2016-09-17 seekingalpha
It's been a brutal couple of years for most stocks in the stem cell sector. Despite the mostly rosy forecasts from the mid tier investment banks over the last few years, most investors in this group have suffered big losses as the optimism over the pipeline potential of stem cell therapies has been met by the reality of extended timelines in conjunction with the endless need for capital. The chart below illustrates this reality:

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

2016-08-02 prnewswire
OSAKA, Japan and LEUVEN, Belgium, Aug. 2, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published in The Lancet. Cx601 is a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease with an inadequate response to at least one conventional or biologic therapy.

TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda

2016-07-05 biospace
OSAKA, Japan and LEUVEN, Belgium, July 5, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease.

20
shares
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

2016-07-05 prnewswire
OSAKA, Japan and LEUVEN, Belgium, July 5, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease.

6
shares
TiGenix: An Undervalued Stem Cell Company Filing For A NASDAQ IPO

2016-03-14 seekingalpha
TiGenix is a leading stem cell biotech with one marketed product and one successful Phase 3 allogeneic treatment for Crohn’s fistulas, Cx601, for which it just filed a MAA.

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!